17.06.2015 • NewsAkzoNobelchlor-alkaliChlorine

Evonik and AkzoNobel in Electroysis JV

Germany’s Evonik and AkzoNobel of the Netherlands have established a 50:50...
Germany’s Evonik and AkzoNobel of the Netherlands have established a 50:50 joint venture to build and operate a membrane electrolysis facility for potassium hydroxide solution and chlorine at AkzoNobel’s Ibbenbüren, Germany, site

Germany’s Evonik and AkzoNobel of the Netherlands have established a 50:50 joint venture to build and operate a membrane electrolysis facility for potassium hydroxide solution and chlorine at AkzoNobel’s Ibbenbüren, Germany, site. The facility, due to start up in the fourth quarter of 2017, will have a nameplate capacity for 130,000 t/y of potassium hydroxide solution and a 82,000 t/y of chlorine.

AkzoNobel will process the chlorine and the hydrogen output directly at the site and market the remainder on the open market, while Evonik will market or further process the potassium hydroxide solution into potassium carbonate at its Lülsdorf, Germany site.

The new joint venture will enable Evonik to supply customers with our potassium derivatives reliably in the long term and also make a “significant contribution” to environmentally-friendly and sustainable production of potassium derivatives, said Evonik exeutive board member Patrik Wohlhauser.

Werner Fuhrmann, AkzoNobel’s executive committee member responsible for specialty chemicals, said the Dutch company’s investment in its
chlor-alkali activities will make its business “even more sustainable.”

Under an EU directive, production of chlorine, potassium hydroxide and sodium hydroxide solutions using mercury electrolysis must be phased out by 2018.

The two companies said the jv – still subject to regulatory clearance – will serve to further strengthen their respective leading market positions.
 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.